World Health Organization: Ageing and health, 1 Oct 2024. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#:~:text=By. Accessed Dec 18 2024

American Cancer Society: Cancer Facts and Figures 2024. American Cancer Society, 2024.Available online. Accessed June 21, 2024.

Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts:. Available online. https://seer.cancer.gov/statistics-network/explorer. Accessed Dec 5, 2024.

Cusatis R, Litovich C, Feng Z, et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective Patient Reported Outcomes data collection within the CIBMTR registry. Transplant Cell Ther. 2024;S2666–6367(24):00482–92. https://doi.org/10.1016/j.jtct.2024.06.021.

Article  Google Scholar 

Jain MD, Spiegel JY, Nastoupil LJ, et al. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2024;42(30):3581–92. https://doi.org/10.1200/JCO.23.02786.

Article  CAS  PubMed  Google Scholar 

Palomba ML, Crombie JL, Nastoupil LJ, et al. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US) Transplantation and Cellular Therapy. Blood. 2024;30(2):S40–1. https://doi.org/10.1016/j.jtct.2023.12.071.

Article  Google Scholar 

Lemoine J, Bachy E, Cartron G, et al. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023;7(21):6589–98. https://doi.org/10.1182/bloodadvances.2023010624.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ustun C, Le-Rademacher J, Wang HL, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019;33(11):2599–609. https://doi.org/10.1038/s41375-019-0477-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Versluis J, Hazenberg CL, Passweg JR, HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):427–36. https://doi.org/10.1016/S2352-3026(15)00148-9.

Article  Google Scholar 

Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–39. https://doi.org/10.1200/JCO.20.03380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russell NH, Hills RK, Thomas A, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. 2022;107(7):1518–27. https://doi.org/10.3324/haematol.2021.279010.

Article  PubMed  Google Scholar 

Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023;29(10):2593–601. https://doi.org/10.1038/s41591-023-02572-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023;389(2):148–57.

Article  CAS  PubMed  Google Scholar 

Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066–77. https://doi.org/10.1016/S1470-2045(22)00339-4.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2020;135(23):2106–9. https://doi.org/10.1182/blood.2019004162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalariya NM, Hildebrandt MAT, Hansen DK, et al. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024;8(17):4679–88. https://doi.org/10.1182/bloodadvances.2024013540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mrózek K, Kohlschmidt J, Blachly JS, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023;37(4):788–98. https://doi.org/10.1038/s41375-023-01846-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6. https://doi.org/10.1001/jama.291.22.2720.

Article  CAS  PubMed  Google Scholar 

Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5(12):1769–73. https://doi.org/10.1001/jamaoncol.2019.2055.

Article  PubMed  Google Scholar 

Flannelly C, Tan BE, Tan JL, et al. Barriers to hematopoietic cell transplantation for adults in the united states: a systematic review with a focus on Age. Biol Blood Marrow Transplant. 2020;26(12):2335–45. https://doi.org/10.1016/j.bbmt.2020.09.013.

Article  PubMed  PubMed Central  Google Scholar 

Pidala J, Craig BM, Lee SJ, et al. Practice variation in physician referral for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2013;48(1):63–7. https://doi.org/10.1038/bmt.2012.95.

Article  CAS  PubMed  Google Scholar 

Tomlinson B, de Lima M, Cogle CR, et al. Transplantation referral patterns for patients with newly diagnosed higher-risk myelodysplastic syndromes and acute myeloid leukemia at academic and community sites in the connect® myeloid disease registry: potential barriers to care. Transplant Cell Ther. 2023;29(7):460.e1-460.e9. https://doi.org/10.1016/j.jtct.2023.04.011.

Article  PubMed  Google Scholar 

Hoffmann MS, Hunter BD, Cobb PW, et al. Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large b cell lymphoma. Transplant Cell Ther. 2023;29(7):440–8. https://doi.org/10.1016/j.jtct.2023.04.003.

Article  CAS  PubMed  Google Scholar 

Sorror ML, Sandmaier BM, Storer BE, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. https://doi.org/10.1001/jama.2011.1558.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ringdén O, Boumendil A, Labopin M, et al. Outcome of allogeneic hematopoietic stem cell transplantation in patients Age >69 years with acute myelogenous leukemia: on behalf of the acute leukemia working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(10):1975–83. https://doi.org/10.1016/j.bbmt.2019.05.037.

Article  PubMed  Google Scholar 

Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26(32):5183–91. https://doi.org/10.1200/JCO.2007.15.5184.

Article  PubMed  Google Scholar 

Hsu J, Chen Z, Shore T, et al. Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(4):789–97. https://doi.org/10.1016/j.bbmt.2019.12.766.

Article  CAS  PubMed  Google Scholar 

Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(8):1479–87. https://doi.org/10.1016/j.bbmt.2015.04.004.

Article  PubMed  PubMed Central  Google Scholar 

Backhaus D, Brauer D, Pointner R, et al. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. Bone Marrow Transplant. 2023;58(1):30–8. https://doi.org/10.1038/s41409-022-01833-0.

Article  CAS  PubMed